Navigation Links
Shareholders to Challenge Johnson & Johnson's Support for Left-Wing Policy Agenda: CEO William C. Weldon to Be Questioned on Firm's Failure to Disclose Financial Information on Firm's ObamaCare Lobbying It Pledged to Release Last Year
Date:4/27/2011

WASHINGTON, April 27, 2011 /PRNewswire-USNewswire/ -- The National Center for Public Policy Research will grill Johnson & Johnson executives over the firm's lobbying for bigger government Thursday, April 28 at the company's annual shareholder meeting in New Brunswick, New Jersey. National Center General Counsel Justin Danhof will demand specific answers about the company's pro-ObamaCare lobbying that Johnson & Johnson CEO William C. Weldon promised to provide but failed to do.

A National Center for Public Policy Research/FreedomWorks poll shows the pharmaceutical giant is vulnerable to a boycott by conservatives.

Johnson & Johnson's favorability among conservatives fell from 69 percent to 19 percent and from 60 percent to 8 percent among tea party activists after participants were informed of the company's lobbying or ObamaCare and cap-and-trade.

In addition to supporting Obama's health care takeover, Johnson & Johnson is a member of the U.S. Climate Action Partnership, a left-wing lobbying coalition formed to promote job-killing global warming regulations such as cap-and-trade.

"From the ObamaCare bill to cap-and-trade legislation, President Obama has been able to count on Johnson & Johnson for aid and comfort. By supporting Obama's economically disastrous policies, Johnson & Johnson is working to increase the power and scope of the federal government at the expense of American liberties and values. Weldon should explain why he is risking Johnson & Johnson's reputation, goodwill and shareholder value to promote a big-government agenda," said Danhof.

Johnson & Johnson is a member of the Pharmaceutical Researchers and Manufacturers of America (PhRMA), which aggressively lobbied for President Obama's health care takeover. At last year's Johnson & Johnson shareholder meeting, Weldon promised National Center Free Enterprise Project Director Dr. Tom Borelli that the firm would disclose precisely how much shareholder money his company spent promoting the ObamaCare legislation.

"Despite repeated requests from the National Center and his own pledge in front of shareholders last year, Weldon still refuses to release those figures. It is time for Weldon to come clean with company stakeholders - many of whom undoubtedly oppose the ObamaCare agenda," said Danhof.

At last year's shareholder meeting, Weldon told Dr. Borelli, "I don't think there is any reputational damage" due to the company's lobbying for ObamaCare's passage.

"The poll numbers don't lie. Tea party activists and conservatives have indicated a willingness to vote with their wallets and forgo Johnson & Johnson products. That could result in real economic loss for shareholders. Weldon needs to explain why he continues to oversee Johnson & Johnson's support of President Obama's unpopular policies instead of upholding his fiduciary duty and protecting the shareholders' investments in the company he is tasked to run," Danhof stated.

To view a transcript of CEO Weldon's conversation with Dr. Borelli at the 2010 shareholder meeting and subsequent communications, see: http://www.nationalcenter.org/ObamacareLobbying.pdf

For more details on the National Center for Public Policy Research/FreedomWorks poll, see: http://www.nationalcenter.org/teapartysurvey.pdf

CONTACT: David Almasi, +1-202-543-4110 x11, +1-703-568-4727, dalmasi@nationalcenter.org, or Judy Kent, +1-703-759-7476, jkent@nationalcenter.org


'/>"/>
SOURCE National Center for Public Policy Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Announces Chairmans Letter to Shareholders
2. Dehaier Medical Chairman and CEO Issues Letter to Shareholders
3. Wound Management Technologies President Writes Letter to Its Shareholders; Cites 3x Revenues Increase Over 2009; CellerateRX® Gaining Traction
4. AFSCME Urges Shareholders to Vote against Executive Compensation at Pfizer (PFE) and Johnson & Johnson (JNJ)
5. Omni Bio Pharmaceutical, Incs. CEO Issues Letter to Shareholders
6. Tongjitang Chinese Medicines Company Shareholders Vote to Approve Merger
7. Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
8. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
9. Tongjitang Chinese Medicines Company Announces Extraordinary General Meeting of Shareholders
10. Caraco Announces Merger Agreement with Sun Pharma; Caraco Public Shareholders to Receive $5.25 Cash per Share
11. Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
Breaking Medicine News(10 mins):